Bristol-Myers names new CEO; Keryx raising $100M;

@FierceBiotech: First on Fierce: Eyeing an IPO, Zymeworks partners up with Celgene on bispecifics. Report | Follow @FierceBiotech

@JohnCFierce: Gene therapy pioneer ReGenX fuels R&D, hiring spree with $30M VC round. Article | Follow @JohnCFierce

@DamianFierce: "Precision medicine" about to get stuffed into 100K bio PRs. "Our precision medicine immunotherapy, with applications in NASH and Ebola ..." | Follow @DamianFierce

> Bristol-Myers Squibb ($BMY) Chief Operating Officer Giovanni Caforio will take over the top spot on May 5 when CEO Lamberto Andreotti will step down and serve as executive chairman of the board. News

> Keryx Biopharmaceuticals ($KERX) is raising $100 million in a stock offering, raising cash to commercialize Auryxia, its treatment for chronic kidney disease. More

> AbbVie ($ABBV) has cut the ribbon on an R&D center on the University of Illinois campus, recruiting grad students to participate in data-minded projects. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Samsung, Welch Allyn back $20M round for contact-free monitoring startup EarlySense. Article | Follow @FierceMedDev

@VarunSaxena2: Bill introduced in Congress to simplify marketing of 'research use only' devices and diagnostics. Story | Follow @VarunSaxena2

@EmilyWFierce: Abbott Labs continues Dx winning streak with bladder cancer biomarker deal. Article | Follow @EmilyWFierce

> Cheetah Medical reveals promising study results for noninvasive blood monitoring tech. News

> Hospira gets FDA nod for wireless infusion pump, finishing up two-year plan to reinvigorate devices. Story

Pharma News

@FiercePharma: Law firms trolling for shareholders to sue Sanofi over alleged kickbacks. News | Follow @FiercePharma

@CarlyHFierce: Depomed drawing on digital savvy--and 250 reps--to relaunch Nucynta franchise. Story | Follow @CarlyHFierce

> Actavis CEO: Pharma believer and Botox user, yes. The Borg? No. More

> Salix Pharmaceuticals eyeing sale in wake of corporate fallout. Article

Drug Delivery News

> Celator's delivery platform results in FDA's fast-track designation for its cancer candidate. Report

> U. Arizona team looks to bring GI delivery vehicle to market. More

> 'Micromotors' made of zinc and polymer actively release drugs at stomach lining. Story

> BD must still pay $350M+ due to safety syringe spat; other punishments delayed pending appeal. Article

> India's Piramal to buy U.S. maker of sterile injectables, antibody drug conjugates. News

Diagnostics News

> Abbott Labs continues Dx winning streak with bladder cancer biomarker deal. More

> SV Bio changes name to Lifecode, plans rollout of NGS cancer assay. Story

> Protein analysis method could act as new cancer biomarker. More

> DNA Electronics snags nanoMR for $24M to gain ground in sepsis market. Story

> GenomeDx expands prostate cancer Dx reach with Medicare coverage deal. Article

Pharma Marketing News

> Depomed drawing on digital savvy--and 250 reps--to relaunch Nucynta franchise. Story

> Embattled Salix hires bankers to weigh a potential sale. More

> J&J eyes long-acting boost for Invega franchise with quick FDA look at new formula. Report

> Lilly snares formulary spots for diabetes meds, no pricing war necessary. Story

> Eisai's copay offer on Belviq has unintended consequences for Arena. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.